TITLE:
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

CONDITION:
Non-Hodgkin's Lymphoma

INTERVENTION:
epratuzumab

SUMMARY:

      Epratuzumab is currently being studied in combination with rituximab, for the treatment of
      patients with low-grade NHL who failed previous chemotherapy and have never received
      rituximab or who received rituximab as a single agent or in combination with chemotherapy as
      their last treatment and who demonstrated a partial response or complete response for at
      least 12 months.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and
             failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior
             rituximab in their last treatment (single agent or in combination with chemotherapy)
             and demonstrated a time to progression of at least 12 months.
      
